4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO-[1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS

Corticotropin releasing factor (CRF) antagonists of Formula (I), and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological...

Full description

Saved in:
Bibliographic Details
Main Author GILLIGAN, PAUL, J
Format Patent
LanguageEnglish
French
Published 19.09.2002
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
TESTING
Online AccessGet full text

Cover

More Information
Summary:Corticotropin releasing factor (CRF) antagonists of Formula (I), and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress. L'invention concerne des antagonistes de corticolibérine (CRF) de formule (I) et leur utilisation dans le traitement de l'anxiété, de la dépression et d'autres troubles psychiatriques neurologiques ainsi que le traitement de maladies liées au système immunologique, cardiovasculaire ou cardiaque et de l'hypersensibilité colique associée à des troubles psychologiques et au stress.
Bibliography:Application Number: WO2002US06837